TARS · ISSUER CIK 1819790
Tarsus Pharmaceuticals, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 6 Tarsus Pharmaceuticals, Inc. insiders reported $0.00 of open-market purchases and $5.2M of sales on SEC Form 4.
↗6 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 6 of 6 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$5.2MInsider selling
−$5.2MNet open-market
Sep 17, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 17, 202616:47 | Sep 15, 2026 | TARS | Director | M · Exercise | — | +201 | 9,575 | +2% | — | ||
| Sep 17, 202616:22 | Sep 15, 2026 | TARS | Director | M · Exercise | — | +302 | 16,956 | +2% | — | ||
| Sep 17, 202616:22 | Sep 15, 2026 | TARS | Director | S · Sell10b5-1 | $78.38 | −12,500 | 94,487 | -12% | −$980K | ||
| Sep 17, 202616:22 | Sep 15, 2026 | TARS | Director | M · Exercise10b5-1 | — | +201 | 106,987 | +0% | — | ||
| Sep 9, 202616:14 | Sep 4, 2026 | TARS | President/CEO and Board Chair, Director | S · Sell10b5-1Late 5d | $90.56 | −10,000 | 827,991 | -1% | −$906K | ||
| Sep 9, 202616:13 | Sep 4, 2026 | TARS | Chief Medical Officer | S · Sell10b5-1Late 5d | $87.50 | −13,953 | 2,547 | -85% | −$1.2M | ||
| Sep 9, 202616:12 | Sep 4, 2026 | TARS | Chief Operating Officer | S · Sell10b5-1Late 5d | $85.00 | −4,564 | 78,532 | -5% | −$388K | ||
| Sep 3, 202616:30 | Sep 2, 2026 | TARS | President/CEO and Board Chair, Director | S · Sell10b5-1 | $80.06 | −10,000 | 837,991 | -1% | −$801K | ||
| Sep 3, 202616:29 | Sep 2, 2026from Sep 1, 2026 | TARS | Chief Medical Officer | S · Sell10b5-1 | $77.56 | −11,578 | 13,320 | -47% | −$898K |